Less Than Half Of ODAC Members Will Participate In Avastin Hearing
This article was originally published in The Pink Sheet Daily
Executive Summary
The "jury" for FDA's June 28-29 hearing on Avastin's breast cancer indication will consist of only six voting participants, five of whom previously called for the claim's withdrawal.
You may also be interested in...
Makena Hearing Panel Is Deep With Maternal-Fetal Medicine Experience, As Preferred By Covis
Of 15 voting members for the Makena advisory committee, more than half have clinical expertise in MFM or perinatology. Covis had requested that a significant proportion of the panel be practicing obstetricians with MFM specialization, while CDER sought a more balanced membership.
Amid Avastin Noise, Shire Quietly Awaits Word On ProAmatine Public Hearing
The jury is still out on whether Shire’s hypotension drug ProAmatine (midodrine) will be the focus of the same type of public hearing recently held on the fate of Avastin’s metastatic breast cancer claim.
Amid Avastin Noise, Shire Quietly Awaits Word On ProAmatine Public Hearing
The jury is still out on whether Shire’s hypotension drug ProAmatine (midodrine) will be the focus of the same type of public hearing recently held on the fate of Avastin’s metastatic breast cancer claim.